ライフサイエンスコーパス: antibody avidity

1 e an effect of age at MCV1 administration on antibody avidity.

2 ycosylation provides a mechanism to modulate antibody avidity.

3 se residues contributing appreciable antigen-antibody avidity.

4 hich suffer from low sensitivity due to poor antibody avidity.

5 ation reaction has no deleterious effects on antibody avidity.

6 ults and explored immune memory by measuring antibody avidity.

7 titers < 1:4) and correlated with increasing antibody avidity.

8 on, reduced isotype class switching, and low antibody avidity.

9 ioration of antibody quality, as measured by antibody avidity.

10 discuss antibody (sub)classes, elaborate on antibody avidity, ability to neutralize pertussis toxin,

11 .0 microg/mL following primary immunization, antibody avidity after booster was low, indicating an ab

12 vitro, apparently because of differences in antibody avidity and accessibility of the respective det

13 Both antibody avidity and ADCC titers were correlated with th

14 Using new analyses of antibody avidity and antibody epitope conformation depen

15 neutralizing antibody titers, an increase in antibody avidity and breadth that was held over time and

16 h classic LTBI, 'resisters' display enhanced antibody avidity and distinct Mtb-specific IgG Fc profil

17 Efficient vaccines potentiate antibody avidity and increase T cell longevity, which co

18 yperimmunized Tc bovines demonstrated higher antibody avidity and more potent cross-neutralizing acti

19 between preexisting anti-dengue virus (DENV) antibody avidity and secondary DENV exposure outcomes, w

20 layed fractional dose increases CSP-specific antibody avidity and somatic hypermutation frequency in

21 S antibodies with Fc receptor (FcR) binding, antibody avidity and T cell specificity to 6 months post

22 ibodies (prefusion and postfusion proteins), antibody avidity, and binding to specific antigenic site

23 e antigenic or undergo changes that increase antibody avidity, and how they can be altered to retain

24 e assessed by using the opsonophagocytic and antibody avidity assay against 8 serotypes and 23 seroty

25 ion of IgG that is HIV-specific, and with an antibody avidity assay based on the Genetic Systems 1/2+

26 We developed an HCV immunoglobulin G (IgG) antibody avidity assay by modifying the Ortho 3.0 HCV en

27 A guanidine-based antibody avidity assay for the identification of recentl

28 ED capture enzyme immunoassay (BED-CEIA), an antibody avidity assay, HIV load, and CD4(+) T-cell coun

29 We used the antibody-avidity assay to study antibody-maturation patt

30 Here, we report antibody and antibody-avidity assays, relying on near-infrared-fluore

31 e-dose and two-dose groups in HPV16 or HPV18 antibody avidity at month 36 for either vaccine.

32 ielded neutralizing antibodies and increased antibody avidity at T2.

33 on, including antibodies to NS1, and highest antibody avidity at the time of challenge.

34 i-pneumococcal capsular polysaccharide (PPS) antibody avidity can influence protective efficacy.

35 that conferred protection had a higher mean antibody avidity constant (21.9 nM(-1)) than the 7 nonpr

36 Antibody avidity correlated with antibody concentration

37 SARS-CoV-2 antibody avidity correlated with duration of infection a

38 level other factors such as HPV exposure or antibody avidity could be important.

39 tibody titer, conformational dependence, and antibody avidity during the first 6 to 10 months followi

40 ified a gender difference in postvaccination antibody avidity (female < male subjects) in adults <65

41 fragment phage-display library analysis, and antibody avidities for HA1 and HA2 domains were measured

42 n glomeruli, and iii) the impact of relative antibody avidity for dsDNA, chromatin fragments, or cros

43 mation of the RBD on the spike and relies on antibody avidity for neutralization.

44 This is the first study to show the role of antibody avidity for the HA1 globular head domain in red

45 However, antibody avidity for these types showed noninferiority,

46 The manipulation of antibody avidity has since emerged as an important desig

47 which corresponded with enhanced anti-spike antibody avidity in blood and enhanced affinity as well

48 Antibody avidity increased over duration of infection an

49 Antibody avidity index is an important parameter for cha

50 re, vaccine efficacy, vaccine effectiveness, antibody avidity index, and T-cell stimulation index.

51 The measles virus antibody avidity indexes were high for all children.

52 The antibody avidity indexes were high for measles and rubel

53 ate in 298 term and 72 preterm neonates that antibody avidity is independent of the timing of materna

54 Antibody avidity is indicative of antibody affinity matu

55 cells, T-zone and GC B-dynamics, IgM and IgG antibodies, avidity maturation, and IC presentation by F

56 allenge dose with, if available, evidence of antibody avidity maturation or an hSBA titer of result >

57 omen assigned to TFV gel demonstrated slower antibody avidity maturation, as determined by the Bio-Ra

58 Such "conjugate vaccines" efficiently induce antibody avidity maturation, isotype switching, and immu

59 e topical TFV but became infected had slower antibody avidity maturation, with potential implications

60 Antibody avidity may affect neutralizing capacity.

61 Antibody avidity may help distinguish, in persons with l

62 e-specific antibodies, rather than a lack of antibody avidity or affinity.

63 mune responses against the tumor by altering antibody avidity or by enhancing innate immunity shifted

64 bly due to technique variation or changes in antibody avidity or titer or in cell panel composition.

65 ENV exposure outcomes, we assessed anti-DENV antibody avidity, represented as avidity index (antibody

66 Antibody avidity significantly increased from 38.08% at

67 CVI activities were directly correlated with antibody avidity, suggesting the importance of antibody

68 ination had no effect on antibody responses, antibody avidity, T-cell responses, or B-cell responses

69 with an existing human herpesvirus 6 (HHV-6) antibody avidity test to detect and distinguish low-avid

70 svirus 7 (HHV-7) indirect immunofluorescence antibody avidity test was developed and used with an exi

71 In conclusion, HIV antibody avidity testing provides a reliable method for

72 rized by an increase in anti-Cryptosporidium antibody avidity that is associated with a decrease in c

73 boosting by the subcutaneous route increased antibody avidity to a greater extent than protein boosti

74 Antibody avidity to Haemophilus influenzae type b (Hib)

75 Antibody avidity to prefusion spike correlated with decr

76 fic antibody epitope repertoire and enhanced antibody avidity to the HA1 (but not the HA2) domain in

77 Antibody avidity (total relative avidity index) did not

78 Tetanus toxoid (TT)-specific antibody avidity was increased in APTB cases in comparis

79 Antibody avidity was investigated using surface plasmon

80 Antibody avidity was investigated.

81 d immunity (CMI), and immunoglobulin G (IgG) antibody avidity were assessed at baseline and 1 month a

82 The kinetics of maturation of antibody avidity were determined prospectively in 23 per

83 immunoglobulin messenger RNA sequencing and antibody avidity were evaluated.

84 gate virus-neutralizing antibody levels, and antibody avidity were lower in CVID responders than in h

85 dy geometric mean concentrations (GMCs), and antibody avidity were measured annually up to month 36.

86 CoV-2 IgG, neutralising antibody titres, and antibody avidity were measured in serum of participants

87 an increase in spike-binding antibodies and antibody avidity with increasing number of exposures to